{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T01:27:51Z","timestamp":1793582871302,"version":"4.5.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,10]],"date-time":"2017-02-10T00:00:00Z","timestamp":1486684800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.ekir.2017.02.008","type":"journal-article","created":{"date-parts":[[2017,2,16]],"date-time":"2017-02-16T03:18:08Z","timestamp":1487215088000},"page":"504-514","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":103,"title":["Anticancer Drug-Induced Acute Kidney Injury"],"prefix":"10.1016","volume":"2","author":[{"given":"Hassan","family":"Izzedine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Perazella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2017.02.008_bib1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1053\/j.ajkd.2014.03.018","article-title":"Acute Kidney Injury Advisory Group of the American Society of Nephrology. The daily burden of acute kidney injury: a survey of U.S. nephrologists on World Kidney Day","volume":"64","author":"Koyner","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2017.02.008_bib2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1056\/NEJMra1214243","article-title":"Acute kidney injury and chronic kidney disease as interconnected syndromes","volume":"371","author":"Chawla","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2017.02.008_bib3","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/ki.2015.115","article-title":"Phenotype standardization for drug-induced kidney disease","volume":"88","author":"Mehta","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2017.02.008_bib4","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.2215\/CJN.02050309","article-title":"Renal vulnerability to drug toxicity","volume":"4","author":"Perazella","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2017.02.008_bib5","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.ccc.2015.06.005","article-title":"Drug-induced acute kidney injury: a focus on risk assessment for prevention","volume":"31","author":"Kane-Gill","year":"2015","journal-title":"Crit Care Clin"},{"key":"10.1016\/j.ekir.2017.02.008_bib6","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/01.ccx.0000184300.68383.95","article-title":"Drug-induced acute kidney injury","volume":"11","author":"Schetz","year":"2005","journal-title":"Curr Opin Crit Care"},{"key":"10.1016\/j.ekir.2017.02.008_bib7","first-page":"457","article-title":"Drug-induced impairment of renal function","volume":"7","author":"Pazhayattil","year":"2014","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"10.1016\/j.ekir.2017.02.008_bib8","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-pharmtox-011112-140317","article-title":"Renal transporters in drug development","volume":"53","author":"Morrissey","year":"2013","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.ekir.2017.02.008_bib9","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"Giacomini","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ekir.2017.02.008_bib10","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2017.02.008_bib11","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1053\/j.ajkd.2015.02.340","article-title":"Thrombotic microangiopathy, cancer, and cancer drugs","volume":"66","author":"Izzedine","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2017.02.008_bib12","doi-asserted-by":"crossref","first-page":"130","DOI":"10.5414\/CNP71130","article-title":"Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution","volume":"71","author":"Glezerman","year":"2009","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.ekir.2017.02.008_bib13","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1056\/NEJMc1316118","article-title":"Thrombotic microangiopathy associated with interferon beta","volume":"370","author":"Hunt","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2017.02.008_bib14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s11255-013-0401-7","article-title":"Thrombotic microangiopathy due to acquired ADAMTS13 deficiency in a patient receiving interferon-beta treatment for multiple sclerosis","volume":"46","author":"Orvain","year":"2014","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.ekir.2017.02.008_bib15","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejca.2009.11.001","article-title":"VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management","volume":"46","author":"Izzedine","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ekir.2017.02.008_bib16","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1055\/s-2005-925474","article-title":"Drug-induced thrombotic microangiopathy","volume":"31","author":"Zakarija","year":"2005","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.ekir.2017.02.008_bib17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11912-016-0514-0","article-title":"Tyrosine kinase inhibitors and vascular toxicity: impetus for a classification system?","volume":"18","author":"Herrmann","year":"2016","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.ekir.2017.02.008_bib18","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2215\/CJN.07311009","article-title":"Treatment with IFN-{alpha}, -{beta}, or -{gamma} is associated with collapsing focal segmental glomerulosclerosis","volume":"5","author":"Markowitz","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2017.02.008_bib19","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/ki.2008.356","article-title":"Bisphosphonate nephrotoxicity","volume":"74","author":"Perazella","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2017.02.008_bib20","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000413416","article-title":"Renal toxicity of nonsteroidal anti-inflammatory drugs","volume":"55","author":"Pirani","year":"1987","journal-title":"Contrib Nephrol"},{"key":"10.1016\/j.ekir.2017.02.008_bib21","doi-asserted-by":"crossref","first-page":"326","DOI":"10.2215\/CJN.03751106","article-title":"High sirolimus levels may induce focal segmental glomerulosclerosis de novo","volume":"2","author":"Letavernier","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2017.02.008_bib22","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.2215\/CJN.01010115","article-title":"Drug-induced glomerular disease: attention required!","volume":"10","author":"Radhakrishnan","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2017.02.008_bib23","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jaut.2014.01.005","article-title":"Diagnosis and classification of drug-induced autoimmunity (DIA)","volume":"48\u201349","author":"Xiao","year":"2014","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.ekir.2017.02.008_bib24","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.2215\/CJN.01910215","article-title":"Drug-induced glomerular disease: immune-mediated injury","volume":"10","author":"Hogan","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2017.02.008_bib25","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1517\/14740338.2015.995089","article-title":"Drug-induced lupus","volume":"14","author":"Rubin","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.ekir.2017.02.008_bib26","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1002\/1529-0131(200011)43:11<2488::AID-ANR16>3.0.CO;2-X","article-title":"Evaluation of antineutrophil cytoplasmic antibody seroconversion induced by minocycline, sulfasalazine, or penicillamine","volume":"43","author":"Choi","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ekir.2017.02.008_bib27","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.autrev.2014.05.005","article-title":"Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: systematic literature review and analysis of a monocentric cohort","volume":"13","author":"Piga","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ekir.2017.02.008_bib28","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.kint.2015.10.008","article-title":"Nonapoptotic cell death in acute kidney injury and transplantation","volume":"89","author":"Linkermann","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2017.02.008_bib29","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/cncr.28478","article-title":"Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib","volume":"120","author":"Brosnan","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.ekir.2017.02.008_bib30","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.lungcan.2013.08.007","article-title":"Acute kidney injury following crizotinib administration for non-small-cell lung carcinoma","volume":"82","author":"Gastaud","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ekir.2017.02.008_bib31","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/ki.2015.30","article-title":"New drug toxicities in the onco-nephrology world","volume":"87","author":"Perazella","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2017.02.008_bib32","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10637-016-0379-y","article-title":"The renal effects of ALK inhibitors","volume":"34","author":"Izzedine","year":"2016","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ekir.2017.02.008_bib33","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1080\/17425255.2016.1214710","article-title":"BRAF and MEK inhibitors in pediatric glioma: new therapeutic strategies, new toxicities","volume":"12","author":"Rizzo","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.ekir.2017.02.008_bib34","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00280-016-3086-7","article-title":"New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanoma","volume":"78","author":"Teuma","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ekir.2017.02.008_bib35","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1002\/cncr.28709","article-title":"Acute renal failure associated with the new BRAF inhibitor vemurafenib: a case series of 8 patients","volume":"120","author":"Launay-Vacher","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.ekir.2017.02.008_bib36","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1001\/jamaoncol.2015.1713","article-title":"Nephrotoxicity of the BRAF inhibitors vemurafenib and dabrafenib","volume":"1","author":"Jhaveri","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ekir.2017.02.008_bib37","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1186\/1471-2407-14-906","article-title":"Increased risk of everolimus-associated acute kidney injury in cancer patients with impaired kidney function","volume":"14","author":"Ha","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ekir.2017.02.008_bib38","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1093\/annonc\/mdt233","article-title":"Acute tubular necrosis associated with mTOR inhibitor therapy: a real entity biopsy-proven","volume":"24","author":"Izzedine","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ekir.2017.02.008_bib39","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1200\/JCO.2002.10.073","article-title":"Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma","volume":"20","author":"Hughes","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ekir.2017.02.008_bib40","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1093\/ndt\/gft241","article-title":"Tubulointerstitial nephritis and cancer chemotherapy: update on a neglected clinical entity","volume":"28","author":"Airy","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2017.02.008_bib41","doi-asserted-by":"crossref","first-page":"713","DOI":"10.5858\/arpa.2011-0565-RA","article-title":"Crystalline nephropathies","volume":"136","author":"Herlitz","year":"2012","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ekir.2017.02.008_bib42","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1517\/14740338.7.2.147","article-title":"Drug-induced crystal nephropathy: an update","volume":"7","author":"Yarlagadda","year":"2008","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.ekir.2017.02.008_bib43","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/ndt\/gft248","article-title":"Molecular mechanisms of crystal-related kidney inflammation and injury. Implications for cholesterol embolism, crystalline nephropathies and kidney stone disease","volume":"29","author":"Mulay","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2017.02.008_bib44","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1093\/ndt\/gfv024","article-title":"Hyperuricemia-induced inflammasome and kidney diseases","volume":"31","author":"Isaka","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2017.02.008_bib45","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/ki.2013.207","article-title":"NALP3-mediated inflammation is a principal cause of progressive renal failure in oxalate nephropathy","volume":"84","author":"Knauf","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2017.02.008_bib46","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/nep.12785","article-title":"The NLRP3 inflammasome in kidney disease and autoimmunity","volume":"21","author":"Hutton","year":"2016","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.ekir.2017.02.008_bib47","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1681\/ASN.2010080798","article-title":"The inflammasomes in kidney disease","volume":"22","author":"Anders","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2017.02.008_bib48","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1681\/ASN.V93506","article-title":"Acute interstitial nephritis","volume":"9","author":"Michel","year":"1998","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2017.02.008_bib49","first-page":"179","article-title":"The outcome of acute interstitial nephritis: risk factors for the transition from acute to chronic interstitial nephritis","volume":"54","author":"Schwarz","year":"2000","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.ekir.2017.02.008_bib50","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1093\/ndt\/gfh485","article-title":"Acute interstitial nephritis: clinical features and response to corticosteroid therapy","volume":"19","author":"Clarkson","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2017.02.008_bib51","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/his.13064","article-title":"Drug-induced nephropathies","volume":"70","author":"Paueksakon","year":"2017","journal-title":"Histopathology"},{"key":"10.1016\/j.ekir.2017.02.008_bib52","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1001\/archinte.1991.00400090095017","article-title":"Iatrogenic renal disease","volume":"151","author":"Davidman","year":"1991","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ekir.2017.02.008_bib53","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1056\/NEJM197408222910803","article-title":"Antitubular basement-membrane antibodies in methicillin-associated interstitial nephritis","volume":"291","author":"Border","year":"1974","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2017.02.008_bib54","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.tips.2011.02.014","article-title":"Anticancer therapy with checkpoint inhibitors: what, where and when?","volume":"32","author":"Garrett","year":"2011","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.ekir.2017.02.008_bib55","doi-asserted-by":"crossref","unstructured":"Izzedine H, Mateus C, Boutros C, et\u00a0al. Renal effects of immune checkpoint inhibitors [e-pub ahead of print]. Nephrol\u00a0Dial Transplant. http:\/\/dx.doi.org\/10.1093\/ndt\/gfw382. Accessed January 19, 2017.","DOI":"10.1093\/ndt\/gfw382"},{"key":"10.1016\/j.ekir.2017.02.008_bib56","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2017.02.008_bib57","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1053\/j.ajkd.2016.02.057","article-title":"Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients","volume":"68","author":"Shirali","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"suppl 1","key":"10.1016\/j.ekir.2017.02.008_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12325-010-0104-8","article-title":"Management of the adverse effects of lenalidomide in multiple myeloma","volume":"28","author":"Gonz\u00e1lez Rodr\u00edguez","year":"2011","journal-title":"Adv Ther"},{"key":"10.1016\/j.ekir.2017.02.008_bib59","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1634\/theoncologist.2010-0070","article-title":"Lenalidomide-induced acute interstitial nephritis","volume":"15","author":"Lipson","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.ekir.2017.02.008_bib60","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1177\/1078155213502569","article-title":"A\u00a0case of DRESS (drug reaction with eosinophilia and systemic symptoms) with acute interstitial nephritis secondary to lenalidomide","volume":"20","author":"Shaaban","year":"2014","journal-title":"J\u00a0Oncol Pharm Pract"},{"key":"10.1016\/j.ekir.2017.02.008_bib61","unstructured":"US FDA. Review of Qualification Data for Biomarkers of Nephrotoxicity Submitted by the Predictive Safety Testing Consortium. www.fda.gov. EMEA\/FDA guideline on detection of drug-induced nephrotoxicity (2009). http:\/\/www.ema.europa.eu. Accessed January 19, 2017."},{"key":"10.1016\/j.ekir.2017.02.008_bib62","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.tox.2014.05.005","article-title":"Urinary microRNA profiling for identification of biomarkers after cisplatin-induced kidney injury","volume":"324","author":"Pavkovic","year":"2014","journal-title":"Toxicology"},{"key":"10.1016\/j.ekir.2017.02.008_bib63","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.tibtech.2015.11.001","article-title":"Kidney-on-a-chip technology for drug-induced nephrotoxicity screening","volume":"34","author":"Wilmer","year":"2016","journal-title":"Trends Biotechnol"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024917300384?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024917300384?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,24]],"date-time":"2022-07-24T03:05:54Z","timestamp":1658631954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024917300384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":63,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S2468024917300384"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2017.02.008","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticancer Drug-Induced Acute Kidney Injury","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2017.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}